Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Inclusion Criteria: * Pathologically confirmed high grade sarcoma of the soft tissue or bone * participants Identified as a proper candidate for ifosfamide-based neoadjuvant therapy * candidates must have operable disease for which a resection is planned * ECOG performance status 0-1 * Hemoglobin ≥ 9.0 g/dL * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement) * INR \< 1.5 or PT/PTT normal.Concurrent anticoagulation therapy with warfarin or heparin allowed * Creatinine ≤ 1.5 times ULN * women of childbearing potential must have negative pregnancy test performed within 7 days prior to start of treatment. * Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy. * A signed informed consent must be obtained prior to any study specific procedures. Exclusion Criteria: * known HIV infection * chronic hepatitis B or C infection * clinically active serious infection \> CTCAE grade 2 * NYHA class III or IV congestive heart failure * unstable angina (i.e., anginal symptoms at rest) or new onset angina within the past 3 months * myocardial infarction within the past 6 months * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 90 mm Hg) despite optimal medical management * thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months * pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks * other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks * Any condition that would impair the ability to swallow whole pills * malabsorption problem * Any known severe hypersensitivity to sorafenib tosylate or any of its excipients * known or suspected allergy to sorafenib tosylate or any agent given in this study * serious nonhealing wound, ulcer, or bone fracture * evidence or history of bleeding diathesis or coagulopathy * significant traumatic injury within the past 4 weeks * major surgery or open biopsy within 4 weeks of starting treatment * Concomitant St. John's wort or rifampin * KNown brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastases. * any condition that impairs patients' ability to swallow pills * any malabsorption problem